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Background/Aims: Small-intestinal bacterial over-
growth (SIBO) is a frequent finding in patients with ir-
ritable bowel syndrome (IBS). Many patients with IBS 
also have abnormal intestinal permeability, which is 
probably due to low-grade inflammation in the in-
testinal mucosa. Our aim was to verify the relation-
ship between SIBO and small-intestinal permeability in 
IBS patients. Methods:  A cohort of 38 IBS patients 
(20 women and 18 men; age range 16-70 years; 
mean age 40.2 years) with symptoms that fulfilled 
Rome-II criteria, and 12 healthy controls (5 women 
and 7 men; age range 25-52 years; mean age: 37.8 
years) were recruited. All subjects underwent lactulose 
breath tests (LBTs) and intestinal permeability tests 
using the polyethylene glycol (PEG) 3350/400 retrieval 
ratio.  Results:  A positive LBT was found in 18.4% 
(7/38) of patients with IBS and 8.3% (1/12) of control 
subjects. Intestinal permeability was significantly in-
creased in patients with IBS compared with the nor-
mal controls (0.82±0.09 vs 0.41±0.05 [mean±SD], re-
spectively; p＜0.05). However, the intestinal perme-
ability did not differ significantly between IBS patients 
with a positive LBT and those with a negative LBT 
(0.90±0.13 and 0.80±0.11, respectively; p＞0.05).  Con-
clusions: Intestinal permeability was increased in pa-
tients with IBS, but this finding did not correlated with 
the occurrence of SIBO. (Gut and Liver 2009; 
3:174-179)
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INTRODUCTION
  Irritable bowel syndrome (IBS) is one of the most com-
mon gastrointestinal diseases. However, due to the 
marked variability of symptoms in patients with IBS, it is 
not easy to develop a unifying hypothesis to explain the 
pathophysiology of this disease. It has been recently sug-
gested that small intestinal bacterial overgrowth (SIBO) 
may provide a framework for understanding the frequent 
clinical observations of IBS patients.
1
  SIBO is a frequent condition in patients with IBS. In 
the previous study, 10-84% of the patients with IBS pre-
sented with bacterial overgrowth using a lactulose breath 
test (LBT).
2-5 Treatment of SIBO with antibiotic and pro-
biotic treatment effectively improved the gas-related 
symptoms of IBS
2,6,7 and these results have been proposed 
as evidence of SIBO as a cause of the symptoms of IBS. 
One of the possible consequences of the host response to 
SIBO is immune activation.
1 SIBO has been regarded as 
an important factor for the development of bacterial 
translocation
8 and bacterial translocation is responsible 
for immune activation.
9,10
    Immune activation is also present in IBS patients. 
There is accumulating evidence of an increased number of 
inflammatory cells in the mucosa
11-13 and lamina prop-
ria,
14 and an altered ratio of an anti-inflammatory cyto-
kine to a proinflammatory cytokine in IBS patients.
15,16 
This inflammation may be a cause or an effect of an al-
tered mucosal barrier in the intestine. Inflammatory con-
ditions in the gut such as acute gastroenteritis
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Crohn’s disease
18 increase gut permeability, and some IBS 
subgroups may also be associated with altered gut 
permeability.
19 However, the previous studies on in-
testinal permeability in IBS patients have produced con-
flicting results and the selection of patients varied among 
the studies.
20,21
    Therefore, the aim of our study was to determine 
whether there was any difference in intestinal perme-
ability between normal subjects and IBS patients, and also 
between the IBS subgroups (IBS with diarrhea [IBS-D] 
and IBS with constipation [IBS-C]) and we wanted to de-
termine if any relationship exists between SIBO and in-
testinal permeability.
MATERIALS AND METHODS
1. Patients
  All the patients exhibited symptoms meeting the Rome- 
II criteria
22; none of the study participants had a clear 
history of inflammatory bowel disease or post-infectious 
I B S ,  w h i c h  i s  d i a g n o s e d  w h e n  p a t i e n t s  h a v e  a t  l e a s t  t w o 
of the following: fever, vomiting, diarrhea or a positive 
stool culture at the onset of IBS symptoms, and the pre-
vious bowel habit has been within normal limits.
23 
Informed written consent was obtained from all patients, 
and approval for the study was received from the local 
ethics committee at the hospital. Twelve normal control 
subjects were included in the study. The control subjects 
had met all of the following criteria: (i) macroscopically 
and histologically normal colonic mucosa,
12
 (ii) no persis-
tent bowel symptoms, (iii) no organic or functional bowel 
disease and (iv) no history of  chronic medical disease. 
The patients with the following criteria were excluded 
from the two groups: (i)  a history of atopy, food allergy 
or asthma based on a detailed medical history, (ii) use of 
mast cell stabilizers or steroids during the month before 
the study, (iii) active diverticulitis or (iv) gastrointestinal 
infection.
12 All the participants underwent colonoscopy in 
order to exclude organic diseases, and the subjects were 
excluded if they had used antibiotics within 2 weeks of 
the LBT. 
2. Questionnaire
    The participants were asked to complete a ques-
tionnaire about their bowel symptoms and the psycho-
logical distress they had experienced over the last 2 
weeks before the interview. The questionnaire included 
the duration of IBS symptoms, and an assessment of the 
following supportive symptoms of IBS
22 on a six-point se-
verity scale: fewer than three bowel movements a week, 
more than three bowel movements a day, hard or lumpy 
stools, loose (mushy) or watery stools, straining during a 
bowel movement, urgency (having to rush to have a bow-
el movement), the feeling of incomplete bowel movement, 
passing mucus (white material) during a bowel movement 
and abdominal fullness, bloating or swelling. To assess 
the psychological well-being and disability of the subjects, 
all the participants were asked to complete the Beck 
Depression Inventory (BDI)
24 and the State-Trait Anxiety 
Inventory (STAI).
25
3. Lactulose breath test 
  A lactulose breath test was performed 2 weeks after 
colonoscopy. After the ingestion of a 100-mL water sol-
ution containing 10 g of lactulose, breath samples were 
taken at 15-min intervals for 3 h. During the test, the 
subjects were forbidden to eat, smoke or exercise. 
Alveolar air samples were obtained after a normal inspira-
tion by having the subjects exhale through a mouthpiece 
into the bags connected by a three-way valve. When the 
first 500 mL of expiratory air filled one plastic bag, then 
the end alveolar air was collected in a second bag (a 1-1 
rubber anesthesia bag adapted with a one-way valve). The 
end alveolar air was then immediately transferred into 50 
mL plastic syringes fitted with two-way stopcocks and the 
air was analyzed within a 2-h period. The H2 and CH4 
concentrations in the breath samples were determined si-
multaneously with a Micro Lyser DP gas chromatograph 
(Quintron Instrument Company, Milwaukee, WI, USA). 
Dry air was used as the carrier gas at a flow rate of 30 
mL/min. The chromatograph was calibrated with using 
H2 and CH4 reference mixtures in compressed air. The 
presence of small bowel bacterial overgrowth was defined 
by the evidence of a peak ＞20 ppm that occurred 15 min 
before the colonic peak. Also, the patients with an ele-
vated fasting H2 and/or CH4 level (＞12-15 ppm) were 
considered positive for bacterial overgrowth.
4. Measurement of intestinal permeability
  Intestinal permeability was also performed 2 weeks af-
ter colonoscopy. Polyethylene glycol (PEG) 3350 was em-
ployed for this study as the permeability probe. PEG 400, 
which acts as an internal control for possible changes in 
intestinal motility and absorption, was added. The two 
components of PEG were administered orally; urine was 
collected for the following 8 hours, and the concentration 
of each PEG molecule was measured using high-perform-
ance liquid chromatography (Waters HPLC system). The 
ratio of urinary excretion of each molecule was then 
determined. The differential urinary excretion of the two 
PEG molecules (the PEG 3350/PEG 400 ratio), which 
corrects for possible changes in intestinal motility and ab-176   Gut and Liver, Vol. 3, No. 3, September 2009
Table 1. Clinical Characteristics and Psychopathology of IBS 
Patients and Controls
IBS patients Controls p-value
No. of patients 38 12
Age (years)* 40.2±2.6 37.8±2.6 NS
Women (%) 52.7 41.7 NS
Description 27 diarrhea
 8 alternating
 3 constipation
Psychopathology*
  STAI-S 43.6±1.8 37.5±2.1 0.04
  STAI-T 44.3±1.7 38.6±1.1 0.01
  BDI 12.6±1.5 7.0±41.4 0.01
IBS, irritable bowel syndrome; STAI, State-Trait Anxiety Inven-
tory; BDI, Beck Depression Inventory; NS, not significant.
*Values are expressed as means±standard error of means 
(SEMs).
Table 2. Prevalence of a Positive LBT among Patients with IBS 
and Controls
LBT positivity (%) p-value
  IBS total  7/38 (18) ＞0.05
  Control 1/12 (8)
  IBS-D  6/27 (22) ＞0.05
  IBS-C  0/8 (0)
  IBS-A   1/3 (33)
LBT, lactulose breath test; IBS, irritable bowel syndrome.
Fig. 1. Comparison of intestinal permeability between patients 
with IBS and controls. Intestinal permeability was significantly 
higher in the IBS patients than in the normal controls 
(p<0.05). 
IBS, irritable bowel syndrome.
sorption, was calculated to provide the “intestinal perme-
ability index”. 
5. Statistical analysis
  Quantitative data were compared using Student’s t test 
with the results expressed as means±SEMs. All the other 
qualitative data comparisons used the χ
2 test. Correlat-
ion between intestinal permeability, the lactulose breath 
test and bowel symptoms was estimated using Pearson's 
correlation coefficient. The alpha level of significance was 
set at p＜0.05. All the analyses were conducted using 
SPSS (version 11.5.0, SPSS Inc., Chicago, IL, USA). 
RESULTS
1. Patients characteristics
  Thirty eight IBS patients (age range: 16-70 years, mean 
age: 40.2 years, 20 women and 18 men) with symptoms 
that fulfilled the Rome-II criteria, and 12 healthy controls 
( a g e  r a n g e :  2 5 - 5 8  y e a r s ,  m e a n  a g e :  3 7 . 8  y e a r s ,  5  w o m e n 
and 7 men) were recruited. Concerning the prevalence of 
bowel habit subtypes, 27 (71%) patients with IBS were 
classified as IBS-D patients, 8 (21%) were classified as 
IBS-C patients and 3 (8%) were classified as IBS-A 
patients. The mean symptom duration of IBS was 78 
months (range: 6-360 months). There was no statistical 
difference of their demographics between two groups (p＞ 
0.05).  In contrast, the depression scores (BDI) and state 
of anxiety scores (STAI-S/T) were significantly higher for 
the patients with IBS than those for the normal controls 
(p<0.05) (Table 1).
2. Positivity of the lactulose breath test in the pa-
tients with IBS and the controls
  O f  t h e  3 8  p a t i e n t s  w i t h  I B S ,  7  w e r e  p o s i t i v e  o n  t h e  
LBT (18.4%), as compared with 1 of 12 control subjects 
(8.3%). The difference between the groups was statisti-
cally insignificant (p＞0.05). The percentage of patients 
with positivity on the LBT was higher for the patients 
with IBS-D (6/27) than those with IBS-C (0/8) and IBS-A 
(1/3); however, this did not reach statistical significance 
(p＞0.05) (Table 2).
3. Intestinal permeability results for the patients 
with IBS and the controls
  The intestinal permeability was significantly increased 
in the patients with IBS compared with the normal con-
trols (0.82±0.09 vs 0.41±0.05, respectively; p＜0.05) 
(Fig. 1). However, no significant difference for intestinal 
permeability was observed among the patients with IBS-D, 
IBS-C and IBS-A (0.85±0.12, 0.74±0.13 and 0.77±0.30, 
respectively; p＞0.05) (Fig. 2).Park JH, et al: SIBO and Intestinal Permeability in IBS   177
Fig. 3. Comparison of intestinal permeability between IBS 
patients with a positive LBT and those with a negative LBT. 
There was no evidence that intestinal permeability was higher 
in patients with a positive LBT than in those with a negative
LBT (p＞0.05). 
IBS, irritable bowel syndrome; LBT, lactulose breath test.
Fig. 2. Comparison of intestinal permeability between IBS sub-
groups and controls. Intestinal permeability did not differ 
significantly among the IBS-D, IBS-C, and IBS-A patients, but 
it was significantly higher in the IBS-D and IBS-C patients 
than in the controls (p<0.05). 
IBS, irritable bowel syndrome.
4. Relation between intestinal permeability, the lac-
tulose breath test and bowel symptoms
  The various symptoms of IBS failed to show any sig-
nificant correlation with intestinal permeability or LBT. 
However, the symptom score of hard stool significantly 
correlated with positivity on the LBT (r=−0.32, p=0.04).
5. Comparison of intestinal permeability between 
patients with positive and negative breath tests
  When the intestinal permeability between the IBS pa-
tients having a positive LBT and those with a negative 
LBT was compared, there was no evidence that the pa-
tients with a positive LBT had increased intestinal perme-
ability compared with those patients with a negative LBT 
(0.90±0.13 and 0.80±0.11, respectively; p＞0.05) (Fig. 3). 
DISCUSSION
  This study revealed that intestinal permeability was sig-
nificantly increased in the patients with IBS compared 
with the normal controls. However, no significant differ-
ence in intestinal permeability was observed among the 
patients with IBS-D, IBS-C and IBS-A; moreover, contrary 
to our expectation, there was no significant difference in 
intestinal permeability between the IBS patients with a 
positive LBT and those IBS patients with a negative LBT. 
  The explanation for why the patients with IBS in this 
study had a lower rate of a positive LBT  compared with 
previous study remains unclear. Rigorous selection cri-
teria for the patients with IBS and differences in race and 
geographic area may have played some role in this 
discrepancy.
2,6 Above all, LBT after two weeks of colono-
scopy may be most responsible for our paucity of abnor-
mal LBTs. Bowel cleansing with polyethylene glycol (PEG, 
Colyte, 4 L) removes the bulk of bacterial flora including 
hydrogen producing ones
26,27 and the higher rates of pos-
itive LBTs for the IBS patients correlated with a longer 
time limit (2 to 3 months) after colonoscopy than did our 
results.
2,4  However, most patients with IBS continued 
complaining of their symptoms when they re-visited 2 
weeks after colonoscopy. Therefore, a proper time limit 
for administering the LBT after colonoscopy should be 
evaluated in the future.
  Our finding of a higher positive rate on the LBT for the 
patients with IBS-D was consistent with a previous re-
port
4 and it also coincided with the result of this study 
that the IBS patients with a positive LBT have less hard 
stool than those with a negative LBT. Therefore, even 
though it was not statistically significant, it might be in-
terpreted that SIBO may be an underlying cause for 
IBS-D.
  Under normal conditions, PEG with a molecular weight 
of 400 or less is absorbed by the intestinal tract and then 
excreted in urine. In contrast, PEGs with a molecular 
mass exceeding 3,350 are poorly absorbed in intestinal 
tract.
28; thus, this has been used to assess intestinal per-
meability under acute conditions such as inflammation, 
shock and burn.
29 The safety of PEG 400 and 4,000 have 
already been established in humans,
30 and PEG as perme-
ability probes can offer three major advantages over 
51Cr-EDTA and small sugars. First, PEG is safe and easy 
to handle. Second, these polymers cover a wide range of 178   Gut and Liver, Vol. 3, No. 3, September 2009
molecular sizes, including those of macromolecules, and 
last, their chromatographic determination is unaffected by 
the presence of sugars found in food and urine, and sub-
jects are not required to adapt their diet prior to taking 
the test.
31 PEG has been criticized for not being suffi-
ciently sensitive to assess intestinal permeability in some 
of the more subtle disorders of barrier function due to 
the low urine excretion levels of PEG 400.
32 However,  
our results of intestinal permeability for the normal sub-
jects are in agreement with those of a previous study,
31 
and when we checked the intestinal permeability twice for 
the same subject, we found that this method gave very 
similar results. Thus, we could verify the reproducibility 
of this method. 
  In the current study, we could not find any difference 
in intestinal permeability between the subgroups of IBS. 
This finding was not consistent with an earlier report that 
the intestinal permeability profiles differ among the IBS 
subtypes with higher small bowel permeability in the pa-
tients with PI-IBS and IBS-D when compared with IBS-C 
patients.
19 The possible causes for this discrepancy are 
the bias from the small number of IBS-C and IBS-A pa-
tients and the different time periods for urine collection. 
The urine samples for this study were collected during 8 
hours, which represents absorption from the small intes-
tine to the proximal colon. The mixed intestinal perme-
ability of the small and large bowel may lead to different 
result. However, we could not exclude the possibility of 
increased intestinal permeability in the patients with 
IBS-C, Since earlier study have reported that the number 
of mast cells was greater in the patients with IBS-C than 
that in the patients with IBS-D and IBS-A,
33 and media-
tors from mast cell plays an important role in the in-
crease of intestinal permeability.
34 Therefore, the exact in-
testinal permeability in the patients with IBS-C remains 
to be established.
  This study could not provide any evidence that a causal 
relationship exists between SIBO and intestinal permea-
bility. Although studies showing the symptom improve-
ment after antibiotic treatment in patients with IBS have 
been used to further support the conclusion that SIBO is 
a pathophysiological factor in IBS,
2,6 this  pathophysiology 
may be explained by alterations of colonic bacterial flora 
that result in symptom improvement, rather than by re-
moval of the bacterial overgrowth.
3 Furthermore, there is 
a possibility that lactulose breath test was not sensitive 
enough to detect the SIBO properly in the small intestine 
and that SIBO does not cause immune activation in the 
G I  t r a c t ,  o r  t h a t  o t h e r  f a c t o r s  s u c h  a s  s t r e s s  a n d  a l c o h o l 
may play more crucial roles in the development of en-
hanced intestinal permeability. Therefore, further study is 
needed in the future to verify the cause of increased in-
testinal permeability in the intestine of patients with IBS 
and the relationship between SIBO, immune activation 
and intestinal permeability.  
REFERENCES
1. Lin HC. Small intestinal bacterial overgrowth: a framework 
for understanding irritable bowel syndrome. JAMA 2004; 
292:852-858.
2. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose 
breath testing correlates with symptom improvement in ir-
ritable bowel syndrome: a double-blind, randomized, place-
bo-controlled study. Am J Gastroenterol 2003;98:412-419.
3. Posserud I, Stotzer PO, Bjornsson ES, Abrahamsson H, 
Simren M. Small intestinal bacterial overgrowth in patients 
with irritable bowel syndrome. Gut 2007;56:802-808. 
4. Lupascu A, Gabrielli M, Lauritano EC, et al. Hydrogen glu-
cose breath test to detect small intestinal bacterial over-
growth: a prevalence case-control study in irritable bowel 
syndrome. Aliment Pharmacol Ther 2005;22:1157-1160.
5. Walters B, Vanner SJ. Detection of bacterial overgrowth in 
IBS using the lactulose H2 breath test: comparison with 
14C-D-xylose and healthy controls. Am J Gastroenterol 
2005;100:1566-1570.
6. Pimentel M, Chow EJ, Lin HC. Eradication of small in-
testinal bacterial overgrowth reduces symptoms of irritable 
bowel syndrome. Am J Gastroenterol 2000;95:3503-3506.
7. Hong KS, Kang HW, Im JP, et al. Effect of probiotics on 
symptoms in Korean adults with irritable bowel syndrome. 
Gut Liver 2009;3:101-107.
8. Berg RD, Garlington AW. Translocation of certain in-
digenous bacteria from the gastrointestinal tract to the 
mesenteric lymph nodes and other organs in a gnotobiotic 
mouse model. Infect Immun 1979;23:403-411.
9. Woodcock NP, Robertson J, Morgan DR, Gregg KL, 
Mitchell CJ, MacFie J. Bacterial translocation and immuno-
histochemical measurement of gut immune function. J Clin 
Pathol 2001;54:619-623.
10. Nieuwenhuijs VB, Verheem A, van Duijvenbode-Beumer 
H, et al. The role of interdigestive small bowel motility in 
the regulation of gut microflora, bacterial overgrowth, and 
bacterial translocation in rats. Ann Surg 1998;228:188-193.
11. Weston AP, Biddle WL, Bhatia PS, Miner PB Jr. Terminal 
ileal mucosal mast cells in irritable bowel syndrome. Dig 
Dis Sci 1993;38:1590-1595.
12. O'Sullivan M, Clayton N, Breslin NP, et al. Increased mast 
cells in the irritable bowel syndrome. Neurogastroenterol 
Motil 2000;12:449-457.
13. Gwee KA, Leong YL, Graham C, et al. The role of psycho-
logical and biological factors in postinfective gut dysfunc-
tion. Gut 1999;44:400-406.
14. Salzmann JL, Peltier-Koch F, Bloch F, Petite JP, Camilleri 
JP. Morphometric study of colonic biopsies: a new method 
of estimating inflammatory diseases. Lab Invest 1989;60: 
847-551.
15. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and 
bifidobacterium in irritable bowel syndrome: symptom re-
sponses and relationship to cytokine profiles. Gastroenter-Park JH, et al: SIBO and Intestinal Permeability in IBS   179
ology 2005;128:541-551.
16. Al-Khatib K, Lin HC. Immune activation and gut microbes 
in irritable bowel syndrome. Gut Liver 2009;3:14-19.
1 7 . F o rg e t  P , S o d o y e z -G o ffa u x  F , Z a p p i te lli A . P e rm e a b ili ty  o f 
the small intestine to [51Cr]EDTA in children with acute 
gastroenteritis or eczema. J Pediatr Gastroenterol Nutr   
1985;4:393-396.
18. Bjarnson I, O'Morain C, Levi AJ, Peters TJ. Absorption of 
51chromium-labeled ethylenediaminetetraacetate in in-
flammatory bowel disease. Gastroenterology 1983;85:318- 
322.
19. Dunlop SP, Hebden J, Campbell E, et al. Abnormal in-
testinal permeability in subgroups of diarrhea-predominant 
irritable bowel syndromes. Am J Gastroenterol 2006;101: 
1288-1294.
20. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. 
Use of surrogate markers of inflammation and Rome cri-
teria to distinguish organic from nonorganic intestinal dis-
ease. Gastroenterology 2002;123:450-460.
21. Dainese R, Galliani EA, De Lazzari F, Di Leo V, Naccarato 
R. Discrepancies between reported food intolerance and 
sensitization test findings in irritable bowel syndrome 
patients. Am J Gastroenterol 1999;94:1892-1897.
22. American Gastroenterology Association. American Gastro-
enterological Association medical position statement: irrita-
ble bowel syndrome. Gastroenterology 2002;123:2105-2107.
23. Spiller RC. Postinfectious irritable bowel syndrome. Gas-
troenterology 2003;124:1662-1671.
24. Beck A, Ward CH, Mendelson M, Mock J, Erbaugh J. An 
inventory for measuring depression. Arch Gen Psychiatry 
1961;4:561-571.
25. Spielberger C. Manual for the state-trait anxiety inventory. 
Palo Alto: Consulting Psychologists Press, 1983. 
2 6 . P e l e d  Y ,  W e i n b e r g  D ,  H a l l a k  A ,  G i l a t  T .  F a c t o r s  a f f e c t i n g 
methane production in humans:  gastrointestinal diseases 
and alterations of colonic flora. Dig Dis Sci 1987;32:267- 
271.
27. DiPalma JA, Brady CE 3rd, Stewart DL, et al. Comparison 
of colon cleansing methods in preparation for colonoscopy. 
Gastroenterology 1984;86:856-860.
28. Schiller LR, Santa Ana CA, Porter J, Fordtran JS. Valida-
tion of polyethylene glycol 3350 as a poorly absorbable 
marker for intestinal perfusion studies. Dig Dis Sci 1997; 
42:1-5.
29. Winne D, Gorig H. Appearance of 14C-polyethylene glycol 
4000 in intestinal venous blood: influence of osmolarity 
and laxatives, effect on net water flux determination. 
Naunyn Schmiedebergs Arch Pharmacol 1982;321:149-156.
3 0. A m eno  H , T ani T , H anasaw a K , K o d am a M . N ew  m etho d 
for the detection of bacterial translocation using intestinal 
permeability with polyethylene glycol 4000. Eur Surg Res 
2000;32:23-29.
31. Loret S, Nollevaux G, Remacle R, et al. Analysis of PEG 
400 and 4000 in urine for gut permeability assessment us-
ing solid phase extraction and gel permeation chromatog-
raphy with refractometric detection. J Chromatogr B Analyt 
Technol Biomed Life Sci 2004;805:195-202.
32. Bjarnason I, MacPherson A, Hollander D. Intestinal perme-
ability: an overview. Gastroenterology 1995;108:1566-1581.
33. Chadwick VS, Chen W, Shu D, et al. Activation of the 
mucosal immune system in irritable bowel syndrome. 
Gastroenterology 2002;122:1778-1783.
34. Jacob C, Yang PC, Darmoul D, et al. Mast cell tryptase 
controls paracellular permeability of the intestine: role of 
protease-activated receptor 2 and beta-arrestins. J Biol Chem 
2005;280:31936-31948.